(Q35840382)

10 August 2017

Antimalarial combinations (English)

1 reference

10 August 2017

0 references

2

1 reference

PubMed ID

15262108

10 August 2017

Peter Gottfried Kremsner

series ordinal

1

object named as

Peter Gottfried Kremsner

1 reference

PubMed ID

15262108

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

364

1 reference

10 August 2017

285-294

1 reference

10 August 2017

9430

1 reference

Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

History and importance of antimalarial drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Resistance to Chloroquine by Plasmodium vivax in Irian Jaya, Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Chloroquine resistance in Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Development of resistance to chloroquine by Plasmodium vivax in Myanmar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Drug resistant falciparum malaria: clinical consequences and strategies for prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Quinine plus clindamycin improves chemotherapy of severe malaria in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Why is it that antimalarial drug treatments do not always work?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Genome sequence of the human malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A molecular marker for chloroquine-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Variations in frequencies of drug resistance in Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Malaria parasites giving rise to recrudescence in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Treatment of malaria: some considerations and limitations of the current methods of assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A trial of artemether or quinine in children with cerebral malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Effect of antipyretic drugs in children with malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

The assessment of antimalarial drug efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Pharmacokinetic interactions of antimalarial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Curing of chloroquine-resistant malaria with clindamycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

The chemotherapy of rodent malaria. LVII. Drug combinations to impede the selection of drug resistance, Part 1: Which model is appropriate?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Antimalarial drug resistance: an increasing problem

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Prevention of Increasing Rates of Treatment Failure by Combining Sulfadoxine‐Pyrimethamine with Artesunate or Amodiaquine for the Sequential Treatment of Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Insights into antifolate resistance from malarial DHFR-TS structures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Epidemiology of drug resistance in malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria--a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Systematic review of amodiaquine treatment in uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Adverse effects of antimalarials. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Antimalarial cocktails--tropical flavours of the month

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A randomized controlled trial on the efficacy of alternative treatment regimens for uncomplicated falciparum malaria in a multidrug-resistant falciparum area of Bangladesh--narrowing the options for the National Malaria Control Programme?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Atovaquone and proguanil for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

The development of Lapdap, an affordable new treatment for malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Genetic susceptibility to adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Clindamycin as an antimalarial drug: review of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

1 reference

7 January 2021

Artemisinins target the SERCA of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Artemisinin, an Endoperoxide Antimalarial, Disrupts the Hemoglobin Catabolism and Heme Detoxification Systems in Malarial Parasite

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Why artemisinin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Artemisinin: mechanisms of action, resistance and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Artesunate combinations for treatment of malaria: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

A randomized, double-blind study on the efficacy and safety of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Fosmidomycin for malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Fosmidomycin, a novel chemotherapeutic agent for malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916680-4

7 January 2021

10.1016/S0140-6736(04)16680-4

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15262108